Clinical trial
A Phase 3 Randomized, Observer-Blind, Controlled Study to Evaluate the Clinical Efficacy of an mRNA Based Seasonal Influenza Vaccine in Older Adults ≥65 Years of Age
NCT07805707 is registered in ClinicalTrials.gov with GlaxoSmithKline as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 3 Randomized, Observer-Blind, Controlled Study to Evaluate the Clinical Efficacy of an mRNA Based Seasonal Influenza Vaccine in Older Adults ≥65 Years of Age
- Lead sponsor
- GlaxoSmithKline
- Phase
- Phase 3
- Overall status
- Recruiting
- Start date
- September 2, 2026
- Completion date
- June 9, 2028
- Enrollment
- 54,000 (estimated)
- Sites
- 163
Conditions
As the registry lists them; a condition with its own page is linked.